Guidelines, Clinical Practice Recommendations, Position Papers and Consensus Statements: Definition, Preparation, Role and Application
- 15 October 2014
- journal article
- editorial
- Published by Georg Thieme Verlag KG in Ultraschall in der Medizin - European Journal of Ultrasound
- Vol. 35 (05) , 395-399
Abstract
Daily clinical decisions at the bedside, rules of operation at hospitals and clinics, and health spending by governments and insurers have become more and more influenced by clinical practice guidelines (CPGs) in last years [1]. Moreover CPGs are increasingly the final argument against or in favour of physicians in medical malpractice litigation. Therefore, addressing the issue of CPGs quality is now unavoidable for many specialties [2] [3] [4] [5] [6] [7]. To this end, editorial teams of medical scientific journals have a key role in keeping and improving the quality of new CPGs [8] [9] [10]. Unfortunately editorial teams, particularly those belonging to subspeciality societies, may not be aware of such responsibility and may be more prone to publish CPGs without peer review [9], being exposed to an increased risk of low quality CPGs. According to the Institute of Medicine [11], CPGs are “statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options”. CPGs are intended to reduce inappropriate variations in clinical care, minimize harm, promote cost-effective practice, and produce optimal health outcomes for patients, and recommendations are the guideline components that are intended to influence practitioner and patient behaviour [12]. We would like to focus here on some critical steps contributing to produce guidelines and clinical practice recommendations of high quality, and to highlight some of them as a support to the ongoing works of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), and its federated societies. CPGs should be systematically developed, and should report both the quality of evidence foundations and the strength of recommendations. The systems for rating quality of evidence and strength of recommendations vary somewhat according to the different bodies releasing the guidelines. For instance, the U. S. Preventive Services Task Force (USPSTF) [13] grades the quality of the overall evidence for a service on a 3-point scale (good, fair, and poor), and describes the strength of recommendations according to five levels, from A (i. e. a level according to which the USPSTF recommends that service: there is high certainty that the net benefit is substantial) to D (the USPSTF recommends against that service: there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits). Moreover, an “I statement” is used when the “current evidence is insufficient to assess the balance of benefits and harms of the service; evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined”. Conversely, since 2009 the English National Institute for Health and Care Excellence (NICE) adopted the Grades of Recommendation Assessment, Development and Evaluation Working Group (GRADE) system [14], grading the quality of evidence as high, moderate, low, and very low for a particular outcome across studies [15]. Despite randomized controlled trials tend to correspond to a high level of evidence, and observational studies to low, the GRADE system encompasses factors that can lower and factors that can increase the rating of the quality of evidence. For instance, grading upwards of an observational study (for example, a cohort or case-control study) may be warranted if the magnitude of the treatment effect is very large (such as severe hip osteoarthritis and hip replacement), if there is evidence of a dose-response relation or if any plausible bias would decrease, rather than increase, the magnitude of the treatment effect [16]. The GRADE system offers two grades of recommendations • strong recommendation: when the desirable effects of an intervention clearly outweigh the undesirable effects, or clearly do not • weak recommendation: when the trade-offs are less certain either because of low quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced [16]. In keeping with the different possible approaches, it is recommended that each CPG specifies how the evidence was searched and graded, and how the recommendations were formulated, as EFSUMB did in the non hepatic applications of contrast enhanced ultrasound [17]. Regardless of the grading system adopted, trustful CPGs should be systematically and transparently developed. Recognized and detailed standards for CPGs development have been established, like those issued by government agencies (e. g. the USPSTF, the NICE) or professional organizations (e. g., American College of Chest Physicians, American College of Cardiology and American Heart Association). Moreover, in recent times the GRADE has become a reference for health organizations (first of all the World Health Organization), medical journals (e. g. British Medical Journal), and professional organizations. In particular, two recent studies disclosed the benefits of the use of the GRADE system on quality of the newly released CPGs [4] [7] issued by both the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. A further useful reference is the AGREE II [18], a 23-item checklist comprising 6 quality domains that help “guidelines developers to follow a structured and rigorous development methodology, to conduct an internal assessment to ensure that their guidance are sound, or to evaluate guidelines from other groups for potential adaptation to their own context”. AGREE II is a reliable tool widely used in the assessment of methodological rigor and transparency of CPG development [7], and can be used also by healthcare providers who wish to undertake their own assessment of a guideline [18]. Whenever acknowledged development standards could not be proven, the journal should be...Keywords
This publication has 14 references indexed in Scilit:
- Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Gastroenterology Practice GuidelinesAmerican Journal of Gastroenterology, 2013
- AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendationsHepatology, 2013
- EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography.Part 2: Clinical ApplicationsUltraschall in der Medizin - European Journal of Ultrasound, 2013
- EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. Part 1: Basic Principles and TechnologyUltraschall in der Medizin - European Journal of Ultrasound, 2013
- The Appropriate Allocation of CEUS in the Diagnostic Algorithm of Liver Lesions: A Debated IssueUltraschall in der Medizin - European Journal of Ultrasound, 2013
- Failure of Clinical Practice Guidelines to Meet Institute of Medicine StandardsArchives of internal medicine (1960), 2012
- In Guidelines We Cannot TrustArchives of internal medicine (1960), 2012
- Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012Ultraschall in der Medizin - European Journal of Ultrasound, 2012
- Assessment of the Quality of Evidence Underlying International Guidelines in Liver DiseaseAmerican Journal of Gastroenterology, 2012
- The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applicationsUltraschall in der Medizin - European Journal of Ultrasound, 2011